GlaxoSmithKline will no longer market its human papillomavirus (HPV) bivalent vaccine, Cervarix, in the United States, according to an industry newsletter report last week.
Cervarix protects against infection from HPV types 16 and 18.
The decision cedes the US market to Merck and its 9-valent human papillomavirus vaccine (Gardasil 9), which protects against infection from HPV types 16, 18, 31, 33, 45, 52, and 58.
“GSK recently made the decision to stop supplying Cervarix in the US due to very low market demand,” a company spokesperson told the newsletter Fierce Pharma.
